低分子肝素

表明低分子肝素在预防血管内膜损伤后内皮增生所致再狭窄的病理过程中发挥重要作用，尤其应损伤早期用药。这将为临床防治术后再狭窄提供了一种新的理论和方法。

It is found that LMWH can play an important role in the pathological process of vascular endothelial hyperplasia after balloon injury restenosis , which provides a new theory and method for the prevention and treatment of restenosis .

考察了低分子肝素溶液在不同pH、不同温度下的水解动力学。

The hydrolytic kinetics of LMWH solution was studied at different pH and temperatures .

穿膜肽R6促进低分子肝素大鼠肠道吸收的研究

Intestinal Absorption Studies on Low Molecular Weight Heparin in Rats Using Cell-penetrating Peptide R_6 as Absorption Enhancer

低分子肝素治疗非ST段抬高急性冠状动脉综合征的疗效

The efficacy observation of low-molecular weight heparins therapy for acute coronary syndrome with non-ST-segment elevation

低分子肝素在非ST段抬高心肌梗死介入治疗中的安全性研究

The Safety and Efficacy of Enoxaparin in PCI for Patients with Non-ST Segment Elevated Myocardial Infarction

低分子肝素钙在老年急性冠脉综合征（非ST段抬高）7年应用分析

The Low Molecular Weight Heparin Calcium Treated the Acute Coronary Syndrome in Old Patients for Seven Years

方法122例患者PCI术后皮下注射低分子肝素60～mg，1次/12～h，共3～d。

Methods 122 patients after PCI received subcutaneous injection of 60 mg LMWH once every 12 hours for three days .

国产与进口低分子肝素治疗ST段抬高性急性心肌梗死对照观察

A controlled observation on imported and domestic low-molecul heparin for patients with acute myocardial infarction with elevated S-T segment

可成功合成本研究所需PLGA，低分子肝素-PLGA涂层工艺成熟。

The synthesis of PLGA and techniques of coating are successful .

低分子肝素对难治性肾病综合征患者血浆PAI-1的影响

Influence of low-molecular-weight heparin on PAI-1 in refractory nephritic syndrome patients

低分子肝素合用阿司匹林肠溶片治疗脑梗死患者DVT的临床观察

Clinical observation of low-molecular-weight heparin and aspirin enteric-coated tablets therapy on deep vein thrombosis

术后根据凝血酶原时间（PT），使用普通肝素或低分子肝素预防性抗凝。

Regular heparin or low-molecular-weight heparin as a prophylactic anticoagulation therapy was maintained during and after ( operation ) as indicated by prothrombin time .

低分子肝素（lowmolecularweightheparin，LMWH）是未分级肝素经化学或酶法解聚而得，相对分子质量为4000～6500。

Low molecular weight heparin ( LMWH ) was obtained by chemical or enzymatic digestion of heparin . Its relative molecular weight was from 4000 Dalton to 6500 Dalton .

目的研究低分子肝素对人肝癌裸鼠模型（LCI-D20）中环氧合酶-2（COX-2）表达的影响。

[ Objective ] To study effects of low molecular weight heparins on cyclooxygenase-2 ( COX-2 ) of hepatocarcinoma in vivo .

低分子肝素钠对IPF患者血清中HGF表达的影响及临床疗效的研究

IPF Patients with Low-molecular-weight Heparin on Serum HGF Expression and Clinical Efficacy Study

方法：rt－PA0.8mg·kg－1，低分子肝素、右旋糖酐40和复方丹参联合应用。

Methods : The dose of rt-PA ( 0.8 mg · kg-1 ) combined with low molecule heparine , Dextran 40 and Red Sager Root compound .

早期应用低分子肝素钙预防危重儿DIC的临床研究

Clinical study of low molecular weight heparin therapy used early in prevention of DIC in critically ill children

低分子肝素抑制bFGF诱导犬动脉平滑肌细胞增殖的体外实验研究

The Inhibitory Effect of Low Molecular Weight Heparin on bFGF-induced Proliferation of Canine Arterial Smooth Muscle Cell : An Experimental Study in Vitro

低分子肝素钙注射液前后7d，采用酶联免疫法测定血浆TNFα-、IL-8水平。

The plasma levels of TNF - α and IL-8 were observed with ELISA assay in 7 days before and after therapy .

目的观察低分子肝素（lowmolecularweightheparin，LMWH）对脑梗死（cerebralinfarction，CI）患者甲襞微循环的动态影响和疗效。

Objective To observe the clinical effect of Low molecular weight heparin ( LMWH ) and its dynamic impact for nail fold microcirculation in patients with cerebral infarction ( CI ) .

结论：低分子肝素是治疗UAP的一种安全、有效的药物。

Conclusions : Low molecular heparin is effective and safety in the treatment of UAP .

结论：小剂量UK与低分子肝素钙联合治疗UA临床效果显著，明显缩短住院时间。

Conclusion : The low dose of UK combined with low molecule heparin calcium can obtain satisfactory therapeutic results of UA and shorten the HT .

低分子肝素预防人工髋关节置换术后DVT的疗效及对血液流变学的影响

The Effect of Low Molecule Heparin on Prevention of Deep veous thrombosis and Hemorheology after Artificial Hip Joint Replacement

低分子肝素与普通肝素治疗急性冠状动脉综合征高危患者：SYNERGY试验的6个月和1年结果

High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin : Outcomes at 6 months and 1 year in the SYNERGY trial

结论低分子肝素联合缬沙坦能显著降低2型早期DN患者UAER，两者联合应用有协同作用。

Conclusion Low molecular heparin combined with valsartan is capable of reducing UAER in patients with early type-2 DN .

目的探讨低分子肝素（LMWH）在冠状动脉支架术中的应用价值及安全性。

Objective To explore the application of low-molecular-weight heparin ( LMWH ) in the procedure of coronary stent implantation .

目的探讨低分子肝素联合尿激酶治疗频发短暂性脑缺血（TIA）发作的疗效和安全性。

Objective To discuss the efficacy and security in the use of the combination of LMWH and urokinase in treating recurrent TIA .

低分子肝素对重度妊高征患者血浆D-D二聚体及血小板聚集功能的影响

Effect of low molecular weight heparin on plasma D-Dimer concentration and platelet aggregation rate in severe pregnancy induced hypertension

结论：预防性使用低分子肝素可以降低髋、膝关节置换术后DVT的发生，不良反应发生率低。

Conclusion : Low molecular weight heparin can reduce the incidence of DVT after hip or knee replacements with a low incidence of side effect .

目的：观察低分子肝素（LMWH）在伴有各种活动性出血患者血透中的应用。

Objective : To observe the effects of low molecular weight heparin ( LMWH ) during hemodialysis in HD patients with active bleeding .